Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients

NCT00393120 | Completed Phase 2

• 2 other identifiers: INCB 9471-201IND No.69,030
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 6

Brief Summary

This study will evaluate the safety, pharmacokinetics and efficacy of the CCR5 antagonist INCB009471 in HIV-1 infected patients who are antiretroviral therapy naïve, or who are not currently on a HAART regimen and have not received any antiretroviral agents for 3 months prior to the Screening visit. Subjects will receive study medication (INCB009471) admnistered orally or placebo once daily with food for 14 days. Clinical safety laboratories, 12-lead electrocardiograms, physical examinations and virologic assessments, including viral load, viral tropism and CD4+ cell count determinations will be performed at the Screening visit and at regularly scheduled visits throughout the study. A blood sample will also be obtained and stored to potentially determine the genotype of the CCR5 receptor. The primary objectives are:

1. 1.Assess the safety and tolerability of 3 doses of INCB009471 or placebo when administered orally, once daily, as monotherapy for 14 days;
2. 2.Determine the pharmacokinetics of 3 doses of INCB009471 or placebo when administered orally, once daily, as monotherapy for 14 days;
3. 3.Evaluate the anti-retroviral activity of 3 doses of INCB009471 or placebo when administered orally, once daily, as monotherapy for 14 days

Conditions

HIV Infections

Keywords

HIV-infection; viral load; CCR5; viral tropism; HIV-1 infection; Treatment Naive

Outcome Measures

Primary Outcomes (1)

• Safety and tolerability will be assessed by monitoring adverse experiences.

  Baseline, every 1-7 days following the initiation of treatment through Day 28 and then at Day 42 or the early study termination visit.

Secondary Outcomes (1)

• The virological response to INCB009471 as monotherapy will be assessed by measuring HIV-1 RNA levels by the Roche Amplicor HIV-1 Monitor® Test, v1.5 - Quantitative.

  Baseline, Days 4, 7, 10, 14, 16, 20 and 28 or the early termination study visit.

Study Arms (3)

Treatment A - INCB009471 100mg IR

EXPERIMENTAL

INCB009471, 100 mg IR orally once daily

Drug: INCB009471

Treatment B - INCB009471 300mg SR

EXPERIMENTAL

INCB009471, 300 mg SR orally once daily

Drug: INCB009471

Treatment C - Placebo

PLACEBO COMPARATOR

Placebo matching INCB009471

Drug: Placebo comparator

Interventions

INCB009471 DRUG

100mg SR (sustained release) orally once daily

Treatment A - INCB009471 100mg IR

Placebo comparator DRUG

Orally once daily

Treatment C - Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Asymptomatic HIV-1 infected individuals that are treatmen naïve (ie less than 2 weeks prior ARV exposure) or treatment experienced subjects who are not currently on HAART and have not received any ARVs for 3 months prior to Screening.
• Males between 18 years and 65 years of age, utilizing adequate contraceptive methods.
• Post menopausal or surgically sterile females between 18 years and 65 years of age. Women of childbearing potential, utilizing adequate contraceptive methods.
• CD4-lymphocyte count \>350 cells/mm3
• HIV-1 RNA copies/ml \> 10,000.
• HIV-1 is CCR5 tropic virus only.
• CCR5 antagonist treatment naive.
• BMI \> 16 to \< 32 kg/m2.
• Have no clinically significant findings on screening evaluations, which in the opinion of the Investigator would interfere with the subject's ability to comply with the protocol.
• Able to comprehend and willing to sign an Informed Consent Form.

You may not qualify if:

• Current or recent (\<30 days) opportunistic infection.
• Presence of CXCR4- or dual-tropic HIV-1 virus at Screening or Baseline assessments.
• Subjects with chronic renal insufficiency
• Personal history of cardiac diseases.
• History or presence of an abnormal ECG.
• History of unstable ischemic heart disease or uncontrolled hypertension.
• History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin.
• Subjects who have received radiation therapy or cytotoxic chemotherapeutic agents and have not recovered from side effects.
• Current treatment or treatment within 30 days or 5 half-lives with another investigational medication or current enrollment in another investigational drug protocol.
• Subjects with unstable medical condition (s), which , in the opinion of the Investigator would compromise their participation in the trial

Sponsors & Collaborators

• Incyte Corporation: lead

Study Sites (6)

Unknown Facility

Los Angeles, California, 90069, United States

Location

Unknown Facility

Washington D.C., District of Columbia, 20007, United States

Location

Unknown Facility

Orlando, Florida, 32803, United States

Location

Unknown Facility

Vero Beach, Florida, 32960, United States

Location

Unknown Facility

Boston, Massachusetts, 02130, United States

Location

Unknown Facility

Annandale, Virginia, 20037, United States

Location

MeSH Terms

Conditions

HIV Infections; Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Slow Virus Diseases

Study Officials

• Richard Levy, MD

  Incyte Corporation

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: October 24, 2006
• First Posted: October 26, 2006
• Study Start: October 1, 2006
• Primary Completion: September 1, 2007
• Study Completion: September 1, 2007
• Last Updated: March 26, 2018

Record last verified: 2018-03

Locations

US (6)